Home / Resource Library / RESULTS FROM EPCORE DLBCL-1: RANDOMIZED PHASE 3 STUDY OF EPCORITAMAB (EPCOR) VS INVESTIGATOR’S CHOICE CHEMOIMMUNOTHERAPY (CIT) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)

RESULTS FROM EPCORE DLBCL-1: RANDOMIZED PHASE 3 STUDY OF EPCORITAMAB (EPCOR) VS INVESTIGATOR’S CHOICE CHEMOIMMUNOTHERAPY (CIT) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)

EHA 2026

Membership Organisation

Healthcare Professional

Affected by Lymphoma

Researcher or Advocate

RESULTS FROM EPCORE DLBCL-1: RANDOMIZED PHASE 3 STUDY OF EPCORITAMAB (EPCOR) VS INVESTIGATOR’S CHOICE CHEMOIMMUNOTHERAPY (CIT) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)